The Wnt antagonist Sost has emerged as a key regulator of bone homeostasis through the modulation of Lrp4/5/6 Wnt coreceptors. In humans, lack of Sclerostin causes sclerosteosis and van Buchem (VB) disease, two generalized skeletal hyperostosis disorders that result from hyperactive Wnt signaling. Unlike sclerosteosis, VB patients lack SOST coding mutations but carry a homozygous 52 kb noncoding deletion that is essential for the transcriptional activation of SOST in bone. We recently identified a putative bone enhancer, ECR5, in the VB deletion region, and showed that the transcriptional activity of ECR5 is controlled by Mef2C transcription factor in vitro. Here we report that mice lacking ECR5 or Mef2C through Col1-Cre osteoblast/osteocyte-specific ablation result in high bone mass (HBM) due to elevated bone formation rates. We conclude that the absence of the Sost-specific long-range regulatory element ECR5 causes VB disease in rodents, and that Mef2C is the main transcription factor responsible for ECR5-dependent Sost transcriptional activation in the adult skeleton. osteocytes S everal rare genetic disorders that interfere with Wnt signaling have provided strong evidence that the "canonical" Wnt signaling pathway is critical in bone (1). The Wnt coreceptor LRP5 has been described as a modulator of bone mass where loss-offunction mutations cause osteoporosis-pseudoglioma syndrome (OPPG) (2), an autosomal recessive disorder characterized by low bone mass and skeletal fragility; conversely, gain-of-function Lrp5 alleles cause high bone mass (HBM) (3). Similar hyperactive osteoblast activity due to elevated Wnt signaling was observed when Sost, a secreted Wnt inhibitor, was mutated in knockout (KO) mice or in sclerosteosis patients who suffer from generalized hyperostosis (4-6). Lrp5 gene targeting or SOST overexpression in transgenic (TG) mice causes osteopenia (3, 7), whereas TG overexpression of G171V Lrp5 allelic variant causes HBM, similar to the Sost KO phenotypes (4, 8, 9) . The recapitulation of the human phenotypes in mouse models supports the conclusion that canonical Wnt signaling plays a critical role in bone metabolism, and points to Sost and Lrp5 as key regulators of bone mass.
The Wnt antagonist Sost has emerged as a key regulator of bone homeostasis through the modulation of Lrp4/5/6 Wnt coreceptors. In humans, lack of Sclerostin causes sclerosteosis and van Buchem (VB) disease, two generalized skeletal hyperostosis disorders that result from hyperactive Wnt signaling. Unlike sclerosteosis, VB patients lack SOST coding mutations but carry a homozygous 52 kb noncoding deletion that is essential for the transcriptional activation of SOST in bone. We recently identified a putative bone enhancer, ECR5, in the VB deletion region, and showed that the transcriptional activity of ECR5 is controlled by Mef2C transcription factor in vitro. Here we report that mice lacking ECR5 or Mef2C through Col1-Cre osteoblast/osteocyte-specific ablation result in high bone mass (HBM) due to elevated bone formation rates. We conclude that the absence of the Sost-specific long-range regulatory element ECR5 causes VB disease in rodents, and that Mef2C is the main transcription factor responsible for ECR5-dependent Sost transcriptional activation in the adult skeleton. osteocytes S everal rare genetic disorders that interfere with Wnt signaling have provided strong evidence that the "canonical" Wnt signaling pathway is critical in bone (1) . The Wnt coreceptor LRP5 has been described as a modulator of bone mass where loss-offunction mutations cause osteoporosis-pseudoglioma syndrome (OPPG) (2) , an autosomal recessive disorder characterized by low bone mass and skeletal fragility; conversely, gain-of-function Lrp5 alleles cause high bone mass (HBM) (3) . Similar hyperactive osteoblast activity due to elevated Wnt signaling was observed when Sost, a secreted Wnt inhibitor, was mutated in knockout (KO) mice or in sclerosteosis patients who suffer from generalized hyperostosis (4-6). Lrp5 gene targeting or SOST overexpression in transgenic (TG) mice causes osteopenia (3, 7) , whereas TG overexpression of G171V Lrp5 allelic variant causes HBM, similar to the Sost KO phenotypes (4, 8, 9) . The recapitulation of the human phenotypes in mouse models supports the conclusion that canonical Wnt signaling plays a critical role in bone metabolism, and points to Sost and Lrp5 as key regulators of bone mass.
The skeletal phenotype describing sclerosteosis patients is similar to what has been documented for van Buchem (VB) disease. Although both VB and sclerosteosis map to the same locus on human chromosome 17 that includes the SOST transcript, the Sclerostin transcription unit was not affected in VB. All VB patients examined to date carry a 52-kb noncoding deletion, 35 kb downstream of SOST that results in the absence of postnatal SOST transcript and protein (10, 11) . Although both sclerosteosis and VB are caused by sclerostin deficiency, the VB phenotype is a result of dysregulated SOST transcription. To identify the potential transcriptional regulatory elements responsible for Sost transcription in bone, we have characterized the expression of a human SOST transgene or an engineered allele corresponding to VB in mice. Only the wild-type (WT) SOST allele faithfully expressed SOST in the adult bone and thereby caused osteopenia, whereas the TG mice carrying the VB deletion allele were indistinguishable from WT (7). Cross-species sequence comparisons combined with in vitro and in vivo enhancer assays identified an evolutionarily conserved candidate enhancer element, termed ECR5, that drove reporter expression in UMR-106 cells and in the skeletal anlage of the murine embryo at embryonic day (E) 14.5 (7) .
Despite wide interest in the manipulation of Sost as a skeletal anabolic therapy, only a modest amount of data has been generated describing the upstream regulatory pathways responsible for its transcription. We have shown in vitro that Sost transcription is controlled by both its proximal promoter and the distal enhancer, ECR5. Specifically, ECR5, which drives reporter gene expression in mature osteoblastic cells, mediates responsiveness to parathyroid hormone (PTH) (12) and TGF-β (13) . PTH suppresses the activity of ECR5-luciferase constructs independently of the SOST promoter and repression occurs via a myocyte enhancer factor 2 (Mef2)-responsive element (12) . Among the four Mef2 family members of transcription factors (Mef2A-D), only Mef2C and Mef2D were shown to be robustly expressed in mineralized bone (14) , and we determined that Mef2C and Sost colocalize in UMR-106 cells and mouse osteocytes (12) . The activity of ECR5 enhancer was increased by exogenous Mef2C and was inhibited by dominant-negative Mef2C cotransfection. Finally, siRNA-mediated knockdown of Mef2C-D significantly suppressed endogenous Sost expression (12) . Together, these results identified Mef2C as a transcriptional regulatory protein in bone, and position it upstream of Sost as a critical transcriptional modulator of the ECR5 candidate enhancer to control bone-specific Sost expression.
In this study, we extend our in vitro results using TG and KO mice. We show that ECR5 is sufficient to drive TG reporter expression in osteocytes, in adult mice. We also show that targeted deletion of ECR5 reduces tissue-specific expression of Sost, increasing bone formation rates and causing HBM. As in VB patients, the hyperostosis in ECR5 KO mice (ECR5 KO ) is milder than observed in sclerosteosis patients and murine Sost KO models, suggesting that the 338-bp ECR5 noncoding deletion is sufficient to recapitulate the phenotypes observed in VB disease. Using a combination of Mef2C;Col1-Cre and Mef2C;Col1-Cre; ECR5-TG compound mice, we show that ECR5-mediated osteocyte expression of Sost is dependent on Mef2C. In addition, targeted ablation of Mef2C in osteoblasts and osteocytes also causes HBM, indicating that Mef2C is a critical regulatory protein in bone and controls Sost expression via ECR5, by functioning as a modulator of Wnt signaling and bone homeostasis. As such, the discovery and characterization of the Mef2C-Sclerostin transcriptional axis has important implications for the anabolic treatment of disorders in which bone loss is a significant component.
Results

ECR5 Drives Transgenic Reporter Expression in Osteoblasts and
Osteocytes. To determine whether ECR5 functions as a tissuespecific enhancer in vivo, we generated two ECR5 TG constructs ( Fig. 1 A and B) . ECR5L included a 2-kb ECR5 fragment upstream of the mouse β-globin minimal promoter driving β-galactosidase (LacZ) ( Fig. 1B; ECR5 LacZ ). 3XECR5s included three tandem copies of a 255bp ECR5 fragment upstream of the 2kb SOST promoter driving topaz-green fluorescent protein (tpzGFP) ( Fig. 1B; 3XECR5 GFP ). ECR5 LacZ expression was compared to Sost LacZ (LacZ replaced Sost in Sost KO ) and was found throughout the skeleton ( Fig. 1 C-F) . In a minority of ECR5 LacZ lines, TG expression was also observed in the vasculature and the kidney (Fig. 1 LacZ and 3XECR5 GFP expression in the neonatal skeleton, with the exception that 3XECR5 GFP also expressed in hypertrophic chondrocytes. Previously, we also observed TG expression in the hypertrophic chondrocytes of SOST TG mice, suggesting that this expression may be specific to the human promoter. These findings allowed us to conclude that the 255-bp ECR5 element is sufficient to drive osteoblast/osteocyte-specific expression in neonatal mice, independently of the SOST promoter. In the adult mice, 3XECR5
GFP expression was more robust in osteocytes than ECR5
LacZ , suggesting that the SOST promoter is also required for high levels of osteocyte-specific expression of Sost.
Mef2C is Required for ECR5-mediated Sost Expression in Osteocytes.
Comparative sequence and transcription factor binding site analysis predicted a Mef2 binding site within the ECR5 element, and this element was shown to be essential for ECR5 activity in vitro (12) . To determine whether Mef2C is required for ECR5-mediated transcriptional activation of Sost in vivo, we compared LacZ expression from either the ECR5 LacZ or the Sost LacZ allele to that of animals where the Mef2C gene has also been removed in osteoblasts and osteocytes with a Col1-Cre TG (15) . This Col1-Cre TG is expressed in both osseous and nonosseous tissues: embryonically in the head and limbs, and postnatally in the skeletal system, predominantly in osteoblasts and osteocytes (16) . In femora and calvaria, the LacZ expression from ECR5
LacZ was abolished in the absence of Mef2C (Fig. 2 A, B , E, and F). Similarly, in the femurs of Sost LacZ mice, >95% of osteocytes positive for Sost did not express LacZ when Mef2C was deleted ( Fig. 2 C and D) . A significant reduction was also observed in calvaria; however, a larger number of Sost-positive cells were retained than in the femur ( Fig. 2 G and H) .
We also examined Mef2C and Sost expression in cortical bone of WT and Mef2C cKO ; Col1-Cre. We found Mef2C mRNA levels to be reduced by ∼70% (Fig. S1A) and Sost by ∼50% (Fig. S1B ) in Mef2C cKO ;Col1-Cre relative to WT controls. Growth plate chondrocytes robustly expressed Mef2C protein in WT and the expression was unchanged in the Mef2C cKO ;Col1-Cre (Fig. 3 A and E). Excision of Mef2C by Col1-Cre eliminated Mef2C protein expression in most osteoblasts and osteocytes relative to WT (Fig. 3 B, C , F, and G); particularly on the periosteal surface, all osteoblasts were negative for Mef2C in Mef2C cKO ;Col1-Cre (Fig.  3F) . The same bone regions that failed to express Mef2C downregulated Sost expression, primarily in osteocytes (Fig. 3 D and H) . These results support a model where ECR5 directs gene expression in osteocytes, and this ECR5-dependent expression requires Mef2C (Fig. 2 B and F) . Similarly, Mef2C is required for the majority of mouse Sost expression in these cells (Fig. 2 D and H (Fig. 4 A-B) . KO mice did not differ in size or weight from their same-sex control littermates, and no overt defects were noted at birth or throughout their lives. At 6 mo of age, microscale computed tomography (μCT) analysis of distal femur and lumbar area (L4) showed that trabecular bone volume fraction (BV/TV) in ECR5
KO was 41% (P < 0.000001) higher than WT (Fig. 4G ). ECR5 KO had significantly higher connectivity density (Conn. D., Fig. 4C ), trabecular number (Tb.N., Fig. 4D ), and lower trabecular separation (Tb. Sp., Fig. 4F ), and structure model index (SMI; Fig. 4H ) compared with WT controls. In the trabecular bone compartment, a significant increase in osteoblast surface (Ob.S) and no significant change in osteoclast surface (Oc.S) was observed. We did observe a significant difference in osteoclast surface to bone surface ratio in both Sost KO ) at the distal femur. Bone formation was also stimulated at the endocortical surface of the femur midshaft in Sost KO , but not in ), compared with 47.5% in ECR5 KO and 46.2% in WT (Fig. 4E) . Consistent results were obtained through histomorphometric characterization of the cancellous bone compartment at the distal femurs, supporting a HBM phenotype in ECR5 KO mice due to elevated bone formation rates (Table 1 ). In humans, the hyperostosis phenotype in VB disease has been described to be significantly milder than those for sclerosteosis (10) . Consistent with the human data, we found the ECR5 KO mice to have a significant increase in bone mass (BV/TV, more than twofold, 104% increase, P < 0.001), which is less dramatic than in Sost KO (more than threefold, 265% increase, P < 1 × 10
); therefore, ECR5 contributes to the VB phenotypes found in the human disease.
ECR5 Is Necessary for Robust Osteocyte Sost Expression in Mice. Sost primarily marked periosteal/cortical and trabecular osteocytes, consistent with its known expression (Fig. S2) . No Sost expression was detected in proliferating or hypertrophic chondrocytes.
ECR5
KO expressed Sost in a significantly lower percentage of osteocytes (Fig. 4J ) relative to WT (Fig. 4I) . To determine the number of osteocytes expressing Sclerostin ∼1000 matrixembedded osteocytes were examined per genotype. Of the 1071 WT osteocytes, 693 (63.4%) expressed Sclerostin (Fig. 4 I and K) . Of the 984 examined ECR5 KO osteocytes, 425 (43.11%) were positive for Sclerostin (Fig. 4 K and J) ; 32% less positive (P < 0.02) ECR5 KO osteocytes relative to WT. We found no changes in Sost expression in ECR5 KO mice relative to WT in kidney, brain, or liver (Fig. S3) . These data indicate that deleting ECR5 reduces the probability that an osteocyte will express high levels of Sost, which quantitatively reduces Sost expression by ∼50% (Fig. S1B ). This reduction is sufficient to boost bone formation and cause HBM consistent with VB phenotypes.
Mef2C Inactivation in Bone Causes HBM Due to Elevated Bone
Formation. We next examined whether targeting Mef2C in osteoblasts/osteocytes phenocopies ECR5 KO and causes HBM in mice. Mef2C cKO ;Col1-Cre mice were born at normal Mendelian ratios and were indistinguishable from their control littermates at birth. After weaning, these mice were slightly smaller, and their tails displayed swelled protrusions due to increased ossification. Analysis of Mef2C cKO ;Col1-Cre femora and lumbar vertebrae by μCT revealed that osteoblast inactivation of Mef2C results in HBM. In every parameter measured (Fig. 5 A-F) , the absolute numbers were highly similar to those determined for ECR5 KO . Mef2C cKO ;Col1-Cre mice had significantly increased Connectivity Density (Fig. 5A) , BV/TV (Fig. 5E) , and decreased SMI (Fig. 5F ) relative to WT controls, and similar to ECR5 KO , did not display a significant difference in the trabecular thickness (Fig.  5C ). BV/TV was increased ∼twofold in Mef2C cKO ;Col1-Cre mice (Fig. 5E) , highly similar to the ECR5 KO (Fig. 4G) . To determine the cellular mechanism by which the HBM phenotype is generated in Mef2C cKO ;Col1-Cre mice, we examined the cancellous bone compartment of the distal femurs of 6-mo-old male mice using dynamic histomorphometry. Similar to ECR5 KO and Sost KO , Mef2C cKO ;Col1-Cre mice also displayed a slight decrease in the osteoclast surface to bone surface ratio; however, this difference was not significant. We also observed a significant increase in the mineral apposition rate (MAR) and the bone formation rate (BFR/TV, Table 1 ), supporting that the removal of Mef2C in osteoblasts and osteocytes phenocopies VB (Fig. 5G) . Recently, it has been reported that Mef2C cKO ; Dmp1-Cre mice display HBM; however, this phenotype was shown to be driven primarily by a reduction in osteoclast activity (19) . To further examine whether reduced osteoclast activity in Mef2C cKO ;Col1-Cre contributes to the HBM phenotype, we measured CTX-1 and RANKL serum levels but found no significant differences between Sost KO , ECR5 KO , and Mef2C cKO ;Col1-Cre mice and WT (Fig. S4) . Furthermore, we examined the expression of activated β-catenin in the femurs of WT, Sost KO , and Mef2C cKO ; Col1-Cre mice and found significantly elevated levels of β-catenin in both Sost KO and Mef2C cKO ;Col1-Cre mice, consistent with an up-regulation of Wnt signaling as a shared mechanism for the HBM in these genetically distinct mice (Fig. S5) .
Discussion
Until recently, members of the Mef2 family of transcriptional factors (Mef2A-D) have only been described as contributors to muscle and cardiovascular function (15, 20) . In 2007, Arnold et al. reported that Mef2C functions as an early regulator of chondrocyte hypertrophy (14) and showed that Mef2C indirectly controls endochondral bone formation (14) . They also reported that Mef2A, -C, and -D are expressed in the emerging endochondral bone, in the late embryonic spongiosa (14) . Subsequently, we showed that Sost expression is modulated by PTH through a Mef2 responsive element, present in the distal ECR5 Sost enhancer (12) . The results of the study presented here reveal the following insights into the molecular basis of transcriptional regulation of Sost in bone: (i) ECR5 is sufficient to drive tissue-specific expression in osteoblasts and osteocytes in vivo (Fig. 1J). (ii) SOST promoter is not required for neonatal expression of ECR5-dependent TGs, but is needed for high levels of TG expression in adult osteocytes ( Fig. 2A vs. 2C and 2E vs. 2G). (iii) In the absence of ECR5 ∼30% less osteocytes express Sost (Fig. 5) .
(iv) ECR5
KO mice have HBM due to elevated bone formation rates resembling VB phenotypes (Fig. 4 E-J) . (v) Mef2C is important in osteocytes for the activity of ECR5-dependent Sost transcription (Fig. 2B, D, F, and H) . (vi) Mef2C deletion from osteoblasts and osteocytes yields HBM and increased bone formation, and displays bone parameters that are similar to ECR5 KO (Fig. 5 A-F) , suggesting that Mef2C is the main transcriptional regulator of ECR5-dependent Sost expression.
Although several regulatory sequences have been characterized and shown to have tissue-specific activity in bone, such as Col1a1(3.6) (21, 22) and Dmp1 (23, 24) the regulatory sequences in these constructs were derived from promoter proximal regions only. ECR5 represents a distal enhancer that has osteoblast-and osteocyte-specific activity in vivo and is located ∼62 kb away from the Sost transcriptional start site. ECR5 is located in the VB region that is deleted from both alleles in VB, and the evidence we present indicates that the human phenotypes are, in part, dependent on the absence of ECR5 and its interaction with the SOST promoter; we also show that ECR5 KO recapitulates VB in mice. Currently, there is only one other report of a distal transcriptional enhancer: the RankL distal regulatory enhancer (DCR) that affects bone mass. When deleted, DCR caused HBM due to reduced osteoclast activity, leading to a lower rate of bone remodeling similar to that observed in humans and mice with hypoparathyroidism (25, 26) .
Because Sost is an inhibitor of an anabolic pathway, there is great interest in elucidating how Sost is regulated transcriptionally and posttranslationally, since modulating Sost levels has profound consequences downstream of Wnt signaling ranging from promoting bone formation (Sost deficiency) (4, 27) to accelerating bone loss (Sost overexpression) (7, 28) , to enhancing bone repair (29) . Here, we provide genetic evidence that Mef2C is important in bone for transcriptional activation of Sost in osteocytes, and hence functions as an upstream regulatory protein and modulator of Wnt signaling. In addition to Sfrp2/3 (19), Sost represents a Mef2C transcriptional target in bone; therefore, other Mef2C-dependent transcripts will likely be found in osteoblasts and osteocytes. It is also likely that, through its known corepressor partners, the type II HDAC proteins (14, 20) , Mef2C may also serve as a key intermediary in the transmission of extracellular signals to the genome in bone. Further studies of Mef2C-Sost-Wnt signaling axis are likely to reveal basic mechanisms of bone formation and homeostasis, and it should be possible to modulate complex metabolic phenotypes through the manipulation of Sost and Mef2C activities in animal models.
Materials and Methods
Generation of ECR5 KO , ECR5L, 3XECR5, and compound Mice. A 338-bp ECR5 region (101782666-101782996; chr 11) was replaced with a floxed Neo cassette using Velocigene (30) and homologous recombination (31) (32) (33) in BAC RP23_252b10. The modified BAC was digested with SgrA1 and electroporated into ES line F1H4 (C57BL/6-129SvJ hybrid). Targeted ES cell clones were identified using Loss of Allele assay and verified by Southern blot. Two clones (VG1369B-C4/VG1369B-D2) were used to generate mice; both lines had the same HBM phenotype. ECR5L and 3XECR5 were PCR amplified from human genomic DNA using 5′-GCCAGTCTACTGCCATTGTCC-3′ 5′-GGGCAGAGATTTCTAGGGGTG-3′ and 5′-AATTCTAGCCACTCCCAGGCA-3′ 5′-AATTCGGCTCCCCCTCATGGCTGGT-3′ primer sets, respectively, and cloned into pCR2.1 vector. ECR5L was cloned into β-globin LacZ vector (gift from M. Nobrega, University of Chicago, Chicago, IL), and three copies of ECR5s were cloned in combination with the human SOST promoter we described (7) and topazGFP (gift from D. Rowe, University of Connecticut, Farmington, CT).
Plasmid DNA was prepared and injected to generate TG mice as described (34 Data represent mean ± SD for parameters measured. Group size n = 5-10. *P < 0.05. BFR, bone formation rate; BS, bone surface; BV, bone volume; MAR, mineral apposition rate; Ob.S, osteoblast surface; Oc.S, osteoclast surface; Tb.Dm, trabecular diameter; Tb.N, trabecular number; Tb.Sp, trabecular separation; TV, total volume; -, no measurements were conducted. ;Col1-Cre mice had higher BMD than WT and less than Sost KO and were indistinguishable from ECR5 KO mice (G).
